JP2011504366A - エンドリシン活性を有する新規ポリペプチド及びその使用 - Google Patents

エンドリシン活性を有する新規ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2011504366A
JP2011504366A JP2010534544A JP2010534544A JP2011504366A JP 2011504366 A JP2011504366 A JP 2011504366A JP 2010534544 A JP2010534544 A JP 2010534544A JP 2010534544 A JP2010534544 A JP 2010534544A JP 2011504366 A JP2011504366 A JP 2011504366A
Authority
JP
Japan
Prior art keywords
polypeptide
cells
bacteriophage
clostridium difficile
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504366A5 (enExample
Inventor
マイケル・ガッソン
メリンダ・マイアー
アルヤン・ナルバド
Original Assignee
プラント バイオサイエンス リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラント バイオサイエンス リミティド filed Critical プラント バイオサイエンス リミティド
Publication of JP2011504366A publication Critical patent/JP2011504366A/ja
Publication of JP2011504366A5 publication Critical patent/JP2011504366A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010534544A 2007-11-26 2008-11-24 エンドリシン活性を有する新規ポリペプチド及びその使用 Pending JP2011504366A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99656307P 2007-11-26 2007-11-26
PCT/GB2008/003923 WO2009068858A1 (en) 2007-11-26 2008-11-24 Novel polypeptides having endolysin activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2011504366A true JP2011504366A (ja) 2011-02-10
JP2011504366A5 JP2011504366A5 (enExample) 2012-01-12

Family

ID=40303496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534544A Pending JP2011504366A (ja) 2007-11-26 2008-11-24 エンドリシン活性を有する新規ポリペプチド及びその使用

Country Status (6)

Country Link
US (2) US20100310522A1 (enExample)
EP (1) EP2225263A1 (enExample)
JP (1) JP2011504366A (enExample)
AU (1) AU2008328584A1 (enExample)
CA (1) CA2706600A1 (enExample)
WO (1) WO2009068858A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513847A (ja) * 2017-03-07 2020-05-21 ノマド バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング クロストリジウムによる対象物の汚染を低減する方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
GB0908949D0 (en) * 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
EP2446028B1 (en) 2009-06-26 2018-04-04 Lysando Aktiengesellschaft Antimicrobial agents
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
CN103857410A (zh) 2011-04-21 2014-06-11 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
KR101177358B1 (ko) 2011-11-10 2012-08-27 서울대학교산학협력단 펩티다아제 활성이 있는 엔돌라이신 ＬｙｓＢ４, 이를 포함하는 식품 및 사료 조성물
GB201215184D0 (en) * 2012-08-24 2012-10-10 Univ Leicester Therapeutic virus
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2017044989A1 (en) * 2015-09-13 2017-03-16 The Rockefeller University Clostridium difficile BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF Clostridium difficile BACTERIA INFECTION
KR101880929B1 (ko) 2016-06-30 2018-08-16 경희대학교 산학협력단 미생물 검출용 융합 단백질, 및 이의 제조방법
US20220112251A1 (en) * 2018-12-24 2022-04-14 University Of South Florida Engineered lysin-human defensin protein
US20220315908A1 (en) * 2019-05-08 2022-10-06 Phagomed Biopharma Gmbh Novel gardnerella endolysins and uses thereof
WO2022182830A1 (en) * 2021-02-25 2022-09-01 Trustees Of Dartmouth College Thermostable clostridium difficile lysins
AU2023304968A1 (en) * 2022-07-05 2025-01-16 Aushealth Corporate Pty Ltd Method of production of modified phage and method of treatment using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516618A (ja) * 2002-02-04 2005-06-09 プロフォス・アクチエンゲゼルシャフト 新規タンパク質

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203333B (it) * 1987-02-16 1989-02-15 Endura Spa Impiego di derivati del metilendiossibenzene con funzione sinergizzante in composizioni per uso insetticida
GB2255561B (en) * 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516618A (ja) * 2002-02-04 2005-06-09 プロフォス・アクチエンゲゼルシャフト 新規タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013023603; Ｇｏｈ　ｅｔ　ａｌ: Ｍｉｃｒｏｂｉｏｌｏｇｙ Ｖｏｌ．１５３, 2007, ｐ．６７６-６８５（２００７） *
JPN6013023605; Ｂｏｒｙｓｏｗｓｋｉ　Ｊ　ｅｔ　ａｌ: Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｂｉｏｌｏｇｙ　ａｎｄ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．２３１, 2006, ｐ．２６６-３７７ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513847A (ja) * 2017-03-07 2020-05-21 ノマド バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング クロストリジウムによる対象物の汚染を低減する方法
JP7214667B2 (ja) 2017-03-07 2023-01-30 ノマド バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング クロストリジウムによる対象物の汚染を低減する方法

Also Published As

Publication number Publication date
EP2225263A1 (en) 2010-09-08
US20160045578A1 (en) 2016-02-18
AU2008328584A1 (en) 2009-06-04
US20100310522A1 (en) 2010-12-09
WO2009068858A1 (en) 2009-06-04
CA2706600A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
JP2011504366A (ja) エンドリシン活性を有する新規ポリペプチド及びその使用
AU2009266982B2 (en) A chimeric bacteriophage lysin with activity against staphylococci bacteria
JP6608697B2 (ja) グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
US20100004321A1 (en) Recombinant Staphylococcal Phage Lysin as an Antibacterial Agent
US9752136B2 (en) Polypeptides having endolysin activity and uses thereof
Heselpoth et al. Enzybiotics: endolysins and bacteriocins
US20160040148A1 (en) Novel Polypeptides Having Endolysin Activity and Uses Thereof
EP2143729A1 (en) New enzymatic active enzyme against Clostridium
Heselpoth et al. Enzybiotics: endolysins and bacteriocins
US20180353575A1 (en) Clostridium difficile bacteriophage lysins for detection and treatment of clostridium difficile bacteria infection
KR101595976B1 (ko) 황색포도알균에 특이적 항균 활성을 가지는 리신 융합 단백질 및 이의 용도
Horgan et al. The use of recombinant phage lysins for the control of bacterial pathogens
장윤지 Characterization and Application of Bacteriophages and Endolysins as Biocontrol Agents to Combat Staphylococcus aureus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141021